CRNX Quote, Financials, Valuation and Earnings

Madrigal Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -39.75%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 67.25%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.76%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,910.42x versus 17.93x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -255.85%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 67.25%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,910.42x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of --. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Palatin Technologies's return on equity of --.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 67.25%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are larger than Palatin Technologies quarterly revenues of --. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is higher than Palatin Technologies's net income of --. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,910.42x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -586.58%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Sutro Biopharma, Inc.'s return on equity of -10195.04%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 67.25%. On the other hand Sutro Biopharma, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 82.77%. Given that Sutro Biopharma, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Sutro Biopharma, Inc. has a beta of 1.615, suggesting its more volatile than the S&P 500 by 61.536%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sutro Biopharma, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Sutro Biopharma, Inc. quarterly revenues of $9.7M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Sutro Biopharma, Inc.'s net income of -$56.9M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sutro Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,910.42x versus 2.94x for Sutro Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.